Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors

Inclusion Criteria:

- Able to provide written informed consent

- Advanced, progressing solid tumor that has no cure

- In Stage 1, any advanced solid malignancy

- In Stage 2, advanced breast cancer, melanoma, or non-small cell lung cancer
(NSCLC)

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2

- Recovered from radiation therapy that may have been given in the last 21 days

- Recovered from surgery

Exclusion Criteria:

- Prior exposure to SNS-032 (previously known as BMS-387032)

- Pregnant or breastfeeding

- Women or male partners of women who are able to have children but are unwilling to
use an approved, effective means of birth control

- Took part in another clinical trial during the last 21 days

- Abnormal lab values for serum potassium, hemoglobin, neutrophils, platelets,
creatinine, AST, ALT, or total bilirubin

- Brain metastases, if patient is not neurologically stable or has needed
corticosteroids or anticonvulsants at anytime within the 28 day period before
enrollment.

- Other active malignancies

- Prior pelvic radiation therapy to ≥ 25% of bone marrow reserve

- Any other condition that would keep the patient from safely taking part in the
clinical trial

Please note: There are additional inclusion/exclusion criteria for this study. Please
contact the study center for additional information and to determine if all study criteria
are met.